Current Research Studies
SC-8003, Phase 1 study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) inhibitor, as a single agent or with Irinotecan in pediatric patients with refractory malignancies
SC-8003_9-ING-41
What is the goal of the study?
1. To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of 9-ING-41 as a single agent and in combination with Irinotecan in pediatric patients with refractory malignancies. 2. To describe the toxicity profile and DLT of 9-ING-41 as a single agent and in combination with Irinotecan in pediatric patients with refractory malignancies. 3. To characterize the pharmacokinetics of 9-ING-41 as a single agent and in combination with Irinotecan when administered to pediatric patients with refractory malignancies.
Who can participate in the study?
Please contact the study team listed below to learn more.